Insider Transactions in Q2 2025 at Schrodinger, Inc. (SDGR)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 18
2025
|
Michael Lynton Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,997
+25.8%
|
-
|
|
Jun 18
2025
|
Gary Sender Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,997
+25.8%
|
-
|
|
Jun 18
2025
|
Jeffrey Chodakewitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,997
+25.8%
|
-
|
|
Jun 18
2025
|
Rosana Kapeller Libermann Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,997
+25.8%
|
-
|
|
Jun 18
2025
|
Nancy Thornberry Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,997
+25.8%
|
-
|
|
Jun 18
2025
|
Bridget A Van Kralingen Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,499
+11.53%
|
-
|
|
Jun 18
2025
|
Richard Friesner Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,997
+1.14%
|
-
|
|
Jun 18
2025
|
Arun Oberoi Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,997
+25.8%
|
-
|
|
Jun 18
2025
|
Gary L Ginsberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,997
+25.8%
|
-
|
|
May 29
2025
|
Mannix Vartan Aklian Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,063
+50.0%
|
-
|
|
May 21
2025
|
Rachit Jain EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
9,375
+20.17%
|
-
|
|
Apr 14
2025
|
Karen Akinsanya President of R&D, Therapeutics |
SELL
Open market or private sale
|
Direct |
16,723
-21.46%
|
$418,075
$25.07 P/Share
|
|
Apr 14
2025
|
Karen Akinsanya President of R&D, Therapeutics |
BUY
Exercise of conversion of derivative security
|
Direct |
16,723
+20.47%
|
$50,169
$3.07 P/Share
|